AGBL2 and rheumatoid arthritis: In addition, anti-CCP2 antibodies have been shown to be highly specific or independently associated with the development of extra-articular manifestations, including ischemic heart disease [10], type 1 diabetes mellitus [11], serositis [12], and subclinical atherosclerosis in patients with RA [13].